gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

ING1 inhibitor of growth family, member 1

Top mentioned proteins: HAD, CaM, Interleukin-2, Lak, IgG1
Papers on ING-1
Isolation and characterization of Flavobacterium columnare from freshwater ornamental goldfish Carassius auratus.
Punia et al., In J Environ Biol, Mar 2015
Furthermore, the strain (ING-1) attributed to genomovar II in 16S rDNA PCR-restriction fragment length polymorphism (PCR-RFLP) and sequence analysis.
Letter to the editor: efficacy and safety of anti-Trop antibodies, R. Cubas, M. Li, C. Chen and Q. Yao, Biochim Biophys Acta 1796 (2009) 309-1.
Alberti et al., In Biochim Biophys Acta, 2010
As for toxicity, the administration of ING-1, a high-affinity, human-engineered anti-Trop-1/Ep-CAM monoclonal antibody, caused cases of acute pancreatitis.
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.
Raum et al., M√ľnchen, Germany. In Cancer Cell Int, 2009
These are murine IgG2a edrecolomab and its murine/human chimeric IgG1 antibody version, and humanized, human-engineered and fully human IgG1 antibodies 3622W94, ING-1, and adecatumumab (MT201), respectively.
Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineere monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors.
Mani et al., New York City, United States. In Ann Oncol, 2007
BACKGROUND: ING-1 is a high-affinity, human engineeredtrade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most adenocarcinomas and is an attractive target for immunotherapy.
ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.
LoBuglio et al., San Antonio, United States. In Clin Cancer Res, 2004
PURPOSE: To determine the feasibility of administration, safety, toxicity, immunogenicity, pharmacokinetics, maximum tolerated dose, and biodistribution of ING-1, a high-affinity, Human-Engineered monoclonal antibody (heMAb) to the Mr 40,000 epithelial cell adhesion molecule Ep-CAM, in patients with advanced adenocarcinomas.
ING-1(heMAb), a monoclonal antibody to epithelial cell adhesion molecule, inhibits tumor metastases in a murine cancer model.
Ammons et al., Berkeley, United States. In Neoplasia, 2003
ING-1(heMAb), a human-engineered monoclonal antibody (MAb) that specifically targets the epithelial cell adhesion molecule (Ep-CAM), kills adenocarcinoma cells in vitro and inhibits tumor growth in vivo.
Technology evaluation: ING-1, XOMA.
Lewis, United States. In Curr Opin Mol Ther, 2003
XOMA is developing ING-1, a human engineered immunoglobulin G1 antibody, as a potential treatment for carcinoma and solid tumors.
In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule.
Dedrick et al., Berkeley, United States. In Neoplasia, 2003
ING-1(heMAb), a Human Engineered monoclonal antibody to epithelial cell adhesion molecule (Ep-CAM), was evaluated for its in vitro and in vivo activity.
Heavy metal coprecipitation with hydrozincite [Zn(5)(CO(3))(2)(OH)(6)] from mine waters caused by photosynthetic microorganisms.
Baldi et al., Cagliari, Italy. In Appl Environ Microbiol, 2000
strain ING-1, was found associated with microalga Chlorella sp.
Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
Wolfe et al., United States. In J Biol Chem, 1997
For this experiment, hCPA1-T268G was chemically conjugated to ING-1, an antibody that binds to the tumor antigen Ep-Cam, or to Campath-1H, an antibody that binds to the T and B cell antigen CDw52.
Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells.
Sondel et al., Madison, United States. In J Immunother (1991), 1992
In addition, an adenocarcinoma reactive human-mouse chimeric monoclonal antibody (ING-1) was able to significantly boost in vivo generated LAK cell-mediated lysis of control, E2-treated, and TAM-treated ER+ and ER- cells.
Immunological effects of levamisole in vitro.
Borden et al., Madison, United States. In J Immunother (1991), 1991
No significant enhancement in the expression of three tumor-associated antigens (880364, NRCO-4, and ING-1) and the intercellular adhesion molecule-1 (ICAM-1) antigen on four human cancer cell lines was observed following in vitro exposure to levamisole.
Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities.
Better et al., Santa Monica, United States. In Hum Antibodies Hybridomas, 1991
Two chimeric mouse-human antibodies, ING-1 (IgG1, kappa) and ING-2 (IgG1, lambda), have been constructed starting from anticarcinoma mouse hybridomas.
Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
Sondel et al., Madison, United States. In Cancer Res, 1990
The mAB included: 3F8 and 14.G2a, which are both specific for neuroblastoma and melanoma and recognize ganglioside GD2, and mAB ING-1, a mouse-human chimeric antibody with constant regions from human IgG1 and kappa chains and variable regions from a mouse mAB that binds to a broad range of human adenocarcinomas.
Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
Oldham et al., Franklin, United States. In Hum Antibodies Hybridomas, 1989
After insertion into a mouse myeloma host cell line, the chimeric genes were expressed successfully and the resulting antibody (ING-1) was purified.
share on facebooktweetadd +1mail to friends